A Novel Automated Immunoassay for Serum NY-ESO-1 and XAGE1 Antibodies in Combinatory Prediction of Response to Anti-Programmed Cell Death-1 Therapy in Non-Small-Cell Lung Cancer

CONCLUSION: Our immunoassay system is useful to predict clinical benefits with NSCLC immune-checkpoint therapy.PMID:33865813 | DOI:10.1016/j.cca.2021.04.008

Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Yumiko Sakai Koji Kurose Kanako Sakaeda Hirotaka Abo Yusuke Atarashi Nobuyuki Ide Toshiyuki Sato Eiichiro Kanda Minoru Fukuda Toru Oga Kenta Noda Mikio Oka Source Type: research